Thrombospondin-1 (TSP-1), a potent inhibitor of angiogenesis that predominantly acts through its receptor CD36, has been reported to inhibit inflammatory lymphangiogenesis, whereas TSP-1 did not inhibit tumor-induced lymphangiogenesis in a chemical skin carcinogenesis model24,25. This evidence concerns the gene CD36 and neoplasm.